Receptos (NASDAQ: RCPT) shareholders had a great day today, with the stock up 37% on exciting phase 2 data for its lead drug candidate RPC1063 in multiple sclerosis. And with a phase 3 trial pitting RPC1063 against Biogen Idec's (NASDAQ:BIIB) Avonex ongoing, there is some exciting data ahead too.

The phase 2 trial met its primary and secondary endpoints and showed what appeared to be a pretty clean safety profile. Of course, the big question is whether Receptos can compete effectively in a multiple sclerosis market littered with heavyweights like Biogen, Novartis (NYSE:NVS), and Teva (NYSE:TEVA).

In the video below, from Market Checkup, the Motley Fool's health care-focused investing show, health care analysts Michael Douglass and David Williamson discuss the trial results and why investors may want to wait for more data.